DDInter150 DDInter478
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Azathioprine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Nucleoside Analog {u} (Pharmacologic Class) includes {v} (Compound) Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daratumumab
Azathioprine {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daratumumab
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daratumumab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daratumumab
Azathioprine {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daratumumab
Azathioprine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Zidovudine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Zidovudine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Daratumumab
Azathioprine (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Daratumumab
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Daratumumab
Azathioprine (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Daratumumab